Published: 16 June 2020
It has now been almost six months since the COVID-19 pandemic started to influence life as we know it, and it has impacted almost every area of life, society, economy, and healthcare severely and globally. We now realise that the road to recovery will be a long one, and we are slowly finding our way in this ‘new normal’.
In our field, many questions have appeared regarding patients with congenital heart disease (CHD), regarding increased susceptibility to the coronavirus and the risk of more severe disease in the presence of CHD, the value of testing and recently reports on the inflammatory disease with some Kawasaki features.
Our aim of the AEPC COVID-19 information page is to present some answers to frequently asked questions, based on continuous monitoring and evaluation of scientific papers. This information is diligently collected by our COVID-19 task force.
We hope that you will find this information useful and invite you to comment and give your input. Please keep in mind the information provided has been written with the best evidence available at the time of writing; and new understandings and findings become available each day.
Katarina Hanseus – AEPC President
Ruth Heying – AEPC Educational Committee
Ina Michel-Behnke – AEPC Councillor
Ornella Milanesi – AEPC Secretary General
Skaiste Senzikaite – AEPC Junior Councillor